Answers are grounded in this paper and cite their sources.
Type V secretory phospholipase A2 (sPLA2-V) has been implicated in several pathophysiological events including inflammation, eicosanoid production, and antibacterial defense. However, its expression has been recognized in only a few organs such as the heart and lung. This study is the first to demonstrate preferential expression of sPLA2-V in human salivary glands by immunohistochemistry and in situ hybridization. In normal tissues, sPLA2-V was expressed in a constitutive manner in serous cells and scarcely in duct epithelia, but not in mucous cells. In contrast in sialoadenitis, sPLA2-V expression was up-regulated in duct epithelia and some mucous cells, while the tumor cells of pleomorphic adenoma strongly expressed the enzyme. We concluded that sPLA2-V in salivary glands may play a role for saliva secretions and anti-bacterial defense, in as well as assist in the progression of sialoadenitis and salivary gland tumor formation through prostaglandin production.
No takes yet. Share an insight, caveat, or question.
Komiyama et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: